Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Ventilation

Therapeutic area intelligence for Ventilation with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
0
Companies
0

Companies

No related entities indexed yet.

Assets

Resmed →

Recent signals(2)

RegulatoryAugust 2, 2026

Resmed Issues Correction for Astral Ventilator Due to Electrical Component Failure

Resmed has issued a correction for certain Astral ventilators due to a failure of an electrical component that may lead to therapy interruption or failure.

RegulatoryJuly 16, 2026

Resmed Astral Ventilators Face Serious Electrical Component Failure Risk

Certain Astral ventilators from Resmed may experience electrical component failures, risking serious injury or death.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.